Mangiferin was verified to inhibit activation of the noncanonical NF-κB pathway by TWEAK treatment in GBM cells, as seen with a reduction in p100-p52 processing and RelB (Fig. 3C). This evidence concerns the gene NFKB2 and glioblastoma.